logo-loader
RNS
viewCello Health PLC

Cello Health PLC - Result of AGM

RNS Number : 5097N
Cello Health PLC
20 May 2020
 

20 May 2020

Cello Health plc

("Cello" or the "Company")

 

Result of AGM

Cello Health plc (AIM: CLL), the global healthcare-focused advisory group, held its Annual General Meeting ("AGM") earlier today at which all resolutions were duly passed.

The votes were as follows:

Resolution

Votes FOR

Votes AGAINST

Votes withheld*





1. Approve the Report & Accounts

72,550,306

-

-





2. Approve the Remuneration Report

72,515,136

17,698

14,472





3. Re-elect Chris Jones

72,531,418

10,000

1,888





4. Re-elect Mark Bentley

72,531,418

10,000

1,888





5. Re-elect Stephen Highley

72,524,418

10,000

1,888





6. Re-appoint auditors

72,210,784

10,000

329,849





7. Section 551 authority

72,444,245

102,500

3,888





8. Section 570 authority

70,879,962

1,628,527

42,144





9. Section 701 authority

70,866,841

24,000

1,657,788

* Please note that a vote withheld is not a vote in law.

 

Enquiries

Cello Health

020 7812 8460

Mark Scott, Chief Executive

 

Mark Bentley, Group Finance Director

 

 

 

Cenkos Securities

  020 7397 8900

Giles Balleny

 

Harry Hargreaves

 

 

 

Buchanan

  020 7466 5000

Mark Court

 

Jamie Hooper

 

Charlotte Slater


 

 

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia, New Jersey, London, Edinburgh, and Farnham.

For further information, please visit: https://cellohealthplc.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGEAASEAELEEFA

Quick facts: Cello Health PLC

Price: 162.5

Market: AIM
Market Cap: £173.37 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist. The research and communications operations both performed well, but there was a common theme to update...

on 05/11/2016